JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on July 13, 2006; DOI: 10.1124/jpet.106.106856

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.106856v1
319/1/414    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Horner, K. A.
Right arrow Articles by Keefe, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Horner, K. A.
Right arrow Articles by Keefe, K. A.


Received for publication April 26, 2006.
Revised July 11, 2006.
Accepted for publication July 11, 2006.

Multiple, high doses of methamphetamine increase the number of preproneuropeptide Y mRNA-expressing neurons in the striatum of rat via a dopamine D1 receptor-dependent mechanism

Kristen A. Horner 1*, Scot C. Westwood 2, Glen R. Hanson 1, Kristen A. Keefe 1

1 University of Utah 2 Westar Corporation/Dugway Engineering

* Address correspondence to: E-mail: kristen.horner{at}pharm.utah.edu

Abstract

Neuropeptide Y (NPY) is a neuropeptide that may be involved with emotional regulation and drug addiction and may act as a neuroprotective agent during toxic insults, such as is associated with multiple, high doses of methamphetamine (METH). The purpose of the present study was to elucidate the nature of METH-induced changes in the NPY system by examining the effect of multiple, high doses of METH on preproNPY (ppNPY) mRNA expression in the striatum and the role that dopamine (DA) D1 and D2 receptors might play in these changes. Rats were administered 5 injections of 10 mg/kg METH at 6-hr intervals, along with the D1 receptor antagonist SCH22390 or the D2 receptor antagonist eticlopride, and were sacrificed 3h after the last dose of METH. The number of neurons expressing ppNPY mRNA in striatum was examined using in situ hybridization histochemistry. An acute dose of METH, as well as multiple, high doses of METH, increased the number of neurons expressing ppNPY mRNA in all regions of striatum examined. There was no change in the number of prosomatostatin (pSOM) mRNA containing neurons. The increase in the number of ppNPY mRNA-expressing neurons was abolished by pretreatment with SCH22390. Eticlopride alone increased the number of ppNPY mRNA-expressing neurons in striatum, and METH treatment did not further increase the number. These findings suggest that exposure to multiple high doses of METH increases the number of neurons expressing detectable levels of ppNPY mRNA, and that this phenomenon is dependent upon DA D1-receptor activation.


Key words: SCH22390, basal ganglia, eticlopride, interneurons, peptide, psychostimulant


This article has been cited by other articles:


Home page
 Stem CellsHome page
W. Murrell, A. Wetzig, M. Donnellan, F. Feron, T. Burne, A. Meedeniya, J. Kesby, J. Bianco, C. Perry, P. Silburn, et al.
Olfactory Mucosa Is a Potential Source for Autologous Stem Cell Therapy for Parkinson's Disease
Stem Cells, August 1, 2008; 26(8): 2183 - 2192.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.